Esophagus to Small Intestine

Inflamm Bowel Dis. 2023;29(3):417−22

Kassim G, Yzet C, Nair N, Debebe A, Rendon A, Colombel JF, Traboulsi C, Rubin DT, Maroli A, Coppola E, Carvello MM, Ben David N, De Lucia F, Sacchi M, Danese S, Spinelli A, Hirdes MMC, ten Hove J, Oldenburg B, Cholapranee A, Riter M, Lukin D, Scherl E, Eren E, Sultan KS, Axelrad J, Sachar DB

Long-term outcomes of the excluded rectum in Crohn’s disease: A multicenter international study


Background: Many patients with Crohn’s disease (CD) require fecal diversion. To understand the long-term outcomes, a multicenter review of the experience with retained excluded rectums was performed.
Methods: The authors reviewed the medical records of all CD patients between 1990 and 2014 who had undergone diversionary surgery with retention of the excluded rectum for at least 6 months and who had at least 2 years of postoperative follow-up.
Results: From all the CD patients in the institutions’ databases, there were 197 who met all inclusion criteria. A total of 92 of 197 patients (46.7%) ultimately underwent subsequent proctectomy, while 105 (53.3%) still had retained rectums at time of last follow-up. Among these 105 patients with retained rectums, 50 (47.6%) underwent reanastomosis, while the other 55 (52.4%) retained excluded rectums. Of these 55 patients whose rectums remained excluded, 20 (36.4%) were symptom-free, but the other 35 (63.6%) were symptomatic. Among the 50 patients who had been reconnected, 28 (56%) were symptom-free, while 22 (44%) were symptomatic. From the entire cohort of 197 cases, 149 (75.6%) either ulti-mately lost their rectums or remained symptomatic with retained rectums, while only 28 of 197 (14.2%), and only 4 of 66 (5.9%) with initial perianal disease, were able to achieve reanastomosis without further problems. Four patients developed anorectal dysplasia or cancer.

Conclusions: In this multicenter cohort of patients with Crohn’s disease who had fecal diversion, fewer than 15%, and only 6% with perianal disease, achieved reanastomosis without experiencing disease persistence.

G. Kassim, M.D., Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, AZ, USA,
E-Mail: gassan.kassim1@gmail.com

DOI: 10.1093/ibd/izac099

Back to overview

this could be of interest:

Ten-day vonoprazan-amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with bismuth-containing quadruple therapy

Am J Gastroenterol. 2023;118(4):627−34

Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg)

Gut. 2023;72:1054−72

More articles on the topic